Solid Biosciences Inc. Payments to Acquire Available-for-sale Securities
Solid Biosciences Inc. (SLDB) reported Payments to Acquire Available-for-sale Securities of $18.74 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-11-13
- Solid Biosciences Inc. payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $5.42M, a 48.75% decline year-over-year.
- Solid Biosciences Inc. payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $4.21M.
- Solid Biosciences Inc. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $9.12M.
- Solid Biosciences Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $10.57M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month |
|---|---|---|---|
| 2018-09-30 | $5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $9.63M derived: sum of 2 quarters · filed 2018-11-13 | $18.74M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $13.32M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $9.12M 10-Q · filed 2018-05-10 | ||
| 2017-09-30 | $10.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $11.14M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $568.00K 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |